The Pharmacy Times® Cardiovascular Health Resource Center is a comprehensive resource for clinical news and expert insights on the health of the heart and blood vessels, including coronary heart disease, stroke, heart failure, heart arrhythmias, and heart valve issues.
August 25th 2025
Evolocumab is now indicated for adults at increased risk for major adverse cardiovascular events (MACE).
Pharmacist-Led DOAC Monitoring Improves Dosing
Patient monitoring significantly improved for patients seen in the pharmacist-led clinic due to greater efforts to order labs per policy and prescribe an appropriate DOAC dose.
Read More
Weighing In on the Recommendations for Oral Anticoagulant Use Following Bariatric Surgery
July 18th 2024Anatomical alterations result in many downstream changes, such as changes in pH, gastric volume, food intake, surface area for absorption, gastric emptying and transit times, and intestinal enzymes and efflux pumps, among others.
Read More
Understand the Effects of Topical Nasal Decongestants on Blood Pressure
Because decongestants act by constricting blood vessels, their use can be problematic in individuals who have hypertension.
Read More
Persistence and Discontinuation Rates for Non-Statin Therapies in ASCVD
Clinical insights on how real-world treatment persistence and discontinuation rates compare between the various non-statin therapies and the factors that contribute to these differences.
Watch
Non-Statin Therapies: Cost Effectiveness and Clinical Evidence Gaps
The expert panel discusses the cost-effectiveness and clinical evidence gaps for non-statin therapies, including PCSK9 inhibitors, inclisiran, and bempedoic acid.
Watch
Clinical Efficacy of Non-Statin Treatment Options in ASCVD
Focusing on PCSK9 inhibitors, inclisiran, and bempedoic acid, the panel compares treatment efficacy and outlines patient factors that influence treatment decisions.
Watch
Evaluating Non-Statin Lipid-Lowering Therapies in ASCVD
Turning the focus to non-statin therapies, the panel outlines logistical barriers and discusses the characteristics that guide treatment selection in patients with ASCVD.
Watch